# Nanoemulgels as Advanced Topical Drug Delivery Systems: Mechanistic Insights and Therapeutic Applications in Skin Disorders, Infections, Wound Healing, and Cancer

**Authors:** Shery Jacob, Anroop B. Nair

PMC · DOI: 10.3390/ph19020247 · 2026-01-31

## TL;DR

Nanoemulgels are advanced drug delivery systems that improve topical treatment for skin disorders, infections, wound healing, and cancer by enhancing drug penetration and patient compliance.

## Contribution

This review introduces nanoemulgels as a novel hybrid system combining nanoemulsions and gels for improved topical drug delivery.

## Key findings

- Nanoemulgels enhance drug penetration through the skin by overcoming the stratum corneum barrier.
- They offer prolonged drug residence time and improved patient compliance for dermatological applications.
- The review highlights formulation methods and characterization techniques for evaluating nanoemulgel performance.

## Abstract

Nanoemulgels have emerged as a promising hybrid drug delivery system that integrates the advantages of nanoemulsions and gels, offering enhanced drug penetration, prolonged residence time, and improved patient compliance. This review provides a comprehensive overview of the therapeutic applications of nanoemulgels in wound healing, microbial infections, skin cancer, and various dermatological disorders. The article begins with an overview of skin architecture and its implications for cutaneous drug delivery, followed by a clear distinction between transdermal and topical drug delivery systems. The mechanisms of drug transport into and through the skin are discussed in detail, highlighting the role of nano-sized carriers, particularly nanoemulsions, in overcoming the stratum corneum barrier. Mechanistic insights into nanocarrier-mediated cutaneous drug transport and their versatility as dermal delivery platforms are described. The formulation aspects of nanoemulgels, including their components and both high-energy and low-energy methods for nanoemulsion preparation, are critically discussed to elucidate their impact on formulation performance. An overview of in vitro characterization techniques and biological screening methods employed to evaluate nanoemulgel performance is presented, along with a tabulated compilation of relevant patents to highlight translational progress. Finally, current challenges, regulatory considerations, and future perspectives are discussed, underscoring the potential of nanoemulgels as a versatile and effective platform for advanced topical drug delivery.

## Linked entities

- **Diseases:** skin cancer (MONDO:0002898)

## Full-text entities

- **Genes:** COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, Fgf7 (fibroblast growth factor 7) [NCBI Gene 14178] {aka Fgf5b, Kgf}, JAK3 (Janus kinase 3) [NCBI Gene 3718] {aka JAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAK}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, STAT1 (signal transducer and activator of transcription 1) [NCBI Gene 6772] {aka CANDF7, IMD31A, IMD31B, IMD31C, ISGF-3, STAT91}, Fgf2 (fibroblast growth factor 2) [NCBI Gene 14173] {aka Fgf-2, Fgf2a, Fgfb, bFGF}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, JAK1 (Janus kinase 1) [NCBI Gene 3716] {aka AIIDE, JAK1A, JAK1B, JTK3}, PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) [NCBI Gene 5562] {aka AMPK, AMPK alpha 1, AMPKa1}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, COX-1 [NCBI Gene 7498537], TSLP (thymic stromal lymphopoietin) [NCBI Gene 85480], COX1 (cytochrome c oxidase subunit I) [NCBI Gene 4512] {aka COI, MTCO1}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, HMGB1 (high mobility group box 1) [NCBI Gene 3146] {aka HMG-1, HMG1, HMG3, SBP-1}
- **Diseases:** pitted keratolysis (MESH:C564818), irritation (MESH:D001523), water (MESH:D000069578), ear edema (MESH:D004427), Cancer (MESH:D009369), diabetes (MESH:D003920), Vitiligo (MESH:D014820), actinic keratosis (MESH:D055623), edema (MESH:D004487), Inflammation (MESH:D007249), neurodegenerative disorders (MESH:D019636), injury to (MESH:D014947), skin and soft tissue infections (MESH:D018461), melanoma (MESH:D008545), fibrosis (MESH:D005355), warts (MESH:D014860), pain (MESH:D010146), mitochondrial dysfunction (MESH:D028361), Skin Disorders (MESH:D012871), rosacea (MESH:D012393), metabolic disorders (MESH:D008659), osteoarthritis (MESH:D010003), psoriatic (MESH:D015535), dandruff (MESH:D063807), Psoriasis (MESH:D011565), pruritus (MESH:D011537), squamous cell carcinoma (MESH:D002294), systemic diseases (MESH:D034721), Burn (MESH:D002056), bleeding (MESH:D006470), Microbial Infections (MESH:D015163), Skin cancer (MESH:D012878), autoimmune inflammatory disease (MESH:D001327), gastric cancer (MESH:D013274), alopecia (MESH:D000505), dermatitis (MESH:D003872), neglected tropical disease (MESH:D058069), Infections (MESH:D007239), nevi (MESH:D009506), cardiovascular diseases (MESH:D002318), Cytotoxicity (MESH:D064420), Dermatological Disorders (MESH:D000168), Wound infections (MESH:D014946), nociceptive (MESH:D059226), histopathological abnormalities (MESH:D000014), metastasis (MESH:D009362), rheumatoid arthritis (MESH:D001172), eczema (MESH:D004485), seborrheic dermatitis (MESH:D012628), HPH (MESH:D006973), follicular disorders (MESH:D005497), colorectal cancer (MESH:D015179), hepatocellular carcinoma (MESH:D006528), fungal (MESH:D009181), immune dysregulation (OMIM:614878), necrotic (MESH:D009336), lipid (MESH:D011017), Atopic dermatitis (MESH:D003876), basal cell carcinoma (MESH:D002280), Erythema (MESH:D004890)
- **Chemicals:** pectin (MESH:D010368), estradiol (MESH:D004958), polysaccharide (MESH:D011134), methoxsalen (MESH:D008730), andrographolide (MESH:C030419), MDA (MESH:D015104), Quercetin (MESH:D011794), vitamin E (MESH:D014810), Carbopol 980 (MESH:C479038), Babchi oil (MESH:C550193), PEG (MESH:D011092), limonene (MESH:D000077222), agar (MESH:D000362), Span 80 (MESH:C018665), Ketoconazole (MESH:D007654), hydroxypropyl methylcellulose (MESH:D065347), guggul extract (MESH:C018562), Carbopol 934 (MESH:C453622), triglycerides (MESH:D014280), polymer (MESH:D011108), tofacitinib citrate (MESH:C479163), phytosterols (MESH:D010840), N-methyl-2-pyrrolidone (MESH:C038678), saquinavir (MESH:D019258), clonidine (MESH:D003000), eucalyptol (MESH:D000077591), deoxycholic acid (MESH:D003840), histamine (MESH:D006632), eucalyptus oil (MESH:D000078122), chitosan (MESH:D048271), P (MESH:D010758), PI (MESH:D010716), dacarbazine (MESH:D003606), acid (MESH:D000143), diacerein (MESH:C025292), sugar (MESH:D000073893), croton oil (MESH:D003436), glucosides (MESH:D005960), alginate (MESH:D000464), Chrysin (MESH:C043561), Carrageenan (MESH:D002351), PEG 400 (MESH:C000595213), Fucidin (MESH:D005672), resveratrol (MESH:D000077185), xanthone (MESH:C009689), rotigotine (MESH:C047508), L-pyrrolidone carboxylic acid (MESH:D011761), benzimidazole (MESH:C031000), polyvinylpyrrolidone (MESH:D011205), triacetin (MESH:D014215), NE (MESH:D009356), isopropanol (MESH:D019840), sodium dodecyl sulfate (MESH:D012967), 2-pyrrolidone (MESH:C028537), xanthan (MESH:C002563), methicillin (MESH:D008712), acyclovir (MESH:D000212), Lauroglycol 90 (MESH:C098387), ethanol (MESH:D000431), Ceramides (MESH:D002518)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Thymus vulgaris (common thyme, species) [taxon 49992], Ligusticum chuanxiong [taxon 49555], Aspergillus niger (species) [taxon 5061], Klebsiella pneumoniae (species) [taxon 573], Aspergillus oryzae (species) [taxon 5062], Streptococcus mutans (species) [taxon 1309], Candida albicans (species) [taxon 5476], Escherichia coli (E. coli, species) [taxon 562], Salmonella (genus) [taxon 590], Allium sativum (garlic, species) [taxon 4682], Fungi (kingdom) [taxon 4751], Salvia rosmarinus (rosemary, species) [taxon 39367], Aiouea amoena (species) [taxon 590013], Staphylococcus aureus (species) [taxon 1280], Rattus norvegicus (brown rat, species) [taxon 10116], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Homo sapiens (human, species) [taxon 9606], Cryptocarya aschersoniana (species) [taxon 1345236], Cuscuta chinensis (species) [taxon 267557], Listeria monocytogenes (species) [taxon 1639], Leishmania (subgenus) [taxon 38568], Punica granatum (granado, species) [taxon 22663], Curcuma longa (turmeric, species) [taxon 136217], Senegalia senegal (gum-arabic, species) [taxon 138043]
- **Cell lines:** L929 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_AR58), ATCC 25175 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), B16F1 — Mus musculus (Mouse), Mouse melanoma, Cancer cell line (CVCL_0158), PCS-201-012 — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_WT12), Hep-3B — Homo sapiens (Human), Childhood hepatocellular carcinoma, Cancer cell line (CVCL_0326), B16F10 — Mus musculus (Mouse), Mouse melanoma, Cancer cell line (CVCL_0159), A431 — Homo sapiens (Human), Skin squamous cell carcinoma, Cancer cell line (CVCL_0037), Balb/c — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0184), HaCaT — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0038), T47D — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0553), B16 — Mus musculus (Mouse), Hybridoma (CVCL_U043), SK-MEL-2 — Homo sapiens (Human), Melanoma, Cancer cell line (CVCL_0069), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030), SK-MEL-30 — Homo sapiens (Human), Cutaneous melanoma, Cancer cell line (CVCL_0039), TE 354 — Homo sapiens (Human), Skin basal cell carcinoma, Cancer cell line (CVCL_1750), NIH3T3 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0594), LX-2 — Homo sapiens (Human), Transformed cell line (CVCL_5792), A375 — Homo sapiens (Human), Amelanotic melanoma, Cancer cell line (CVCL_0132)

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12944252/full.md

---
Source: https://tomesphere.com/paper/PMC12944252